August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
David Heredia: Long-term Data from the VISION Trial
Jul 15, 2025, 15:15

David Heredia: Long-term Data from the VISION Trial

David Heredia, Head of Oncology Department at Punta Médica Hospital, shared a post on X:

“Long-term data from the VISION trial shows:

Tepotinib offers durable responses in METex14 skipping NSCLC.

  • ORR: 51–57%
  • PFS: ~6–8.5 months
  • OS: ~20–22 months
  • Liquid biopsy effective for detection”

Title: Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer

Authors: Paul K. Paik, Wade T. Iams, Hatim Husain, Richard M. O’Hara, Jr, Emmanuel Adewusi, Xiuning Le

You can read the Full Article on Cancer Treatment Reviews.

David Heredia: Long-term Data from the VISION Trial

More posts featuring David Heredia on OncoDaily.